Catheter Precision, Inc. SEC Filings

Catheter Precision, Inc. completed a private financing on July 30, 2026, issuing 2,821 shares of Series C-4 Convertible Preferred Stock, par value $0.0001 and stated value $1,000 per share, for aggregate gross proceeds of $2,821,000.00. The securities were issued to investors exercising an Additional Investment Right under a March 9, 2026 Securities Purchase Agreement.

The Series C-4 terms are set out in a Certificate of Designation filed July 27, 2026 in Delaware. Dawson James Securities, Inc. acted as placement agent and received customary fees and expenses. The company plans to use net proceeds for working capital, general corporate purposes and to redeem all outstanding Series B Convertible Preferred Stock. The Series C-4 Preferred Stock ranks senior to common stock for dividends and liquidation rights, and any conversion into common stock will dilute existing common shareholders. The issuance relied on exemptions under Section 4(a)(2) and Rule 506(b) of Regulation D, with sales only to accredited investors and subject to transfer restrictions.

Catheter Precision, Inc. filed an amended report to add full-year 2024–2025 financial statements for Fly Flyte, Inc. and Ponderosa Air LLC (together “FLYTE”), which it acquired from Creatd, Inc. on March 9, 2026, plus unaudited pro forma results reflecting this acquisition.

FLYTE operates a private aviation platform. In 2025 it generated $986 thousand of service revenue but recorded a net loss of $4.8 million, negative operating cash flow of $2.3 million, and an accumulated deficit of $17.2 million. Year-end cash was $26 thousand with a working capital deficit of $4.4 million and stockholders’ deficit of $4.7 million.

Auditors raised substantial doubt about FLYTE’s ability to continue as a going concern due to recurring losses, negative cash flows, a leveraged balance sheet, and litigation and lease settlements, despite debt restructurings, gains on extinguishment of debt and leases, and capital contributions from prior owners. After the acquisition, Catheter Precision committed to provide financial support and is pursuing additional financing to fund ongoing operations.

Catheter Precision, Inc. received a Schedule 13G reporting that SEG JETS SPV I, LLC, a Delaware limited liability company, is a significant shareholder. SEG JETS SPV I, LLC reports beneficial ownership of 1,065,620 shares of common stock, with shared voting and dispositive power over all of these shares and no sole power.

This position represents 9.79% of Catheter Precision’s common stock, based on 10,880,868 shares outstanding as verified with the issuer on July 17, 2026. The filing is signed by Joseph Reda, as Manager of SEG JETS SPV I, LLC.

Catheter Precision, Inc. completed the closing of a private placement of 3,470 shares of newly designated Series C-3 Convertible Preferred Stock, each with a $1,000 stated value, for aggregate gross proceeds of $3,470,000. The transaction followed prior stockholder approval and effectiveness of a Form S-1 registering resale of common shares issuable upon conversion.

The Series C-3 Preferred Stock is convertible at the holder’s option into common stock at an initial conversion price of $0.632 per share, subject to a $0.35 floor price the company may waive and customary anti-dilution adjustments. Conversion is limited by a 4.99% beneficial ownership cap, which holders may increase to 9.99% with 61 days’ notice. The preferred shares rank senior to common stock for dividends and liquidation, and conversion will dilute existing common holders. A Certificate of Designation filed on July 14, 2026 formally designated the 3,470 Series C-3 shares. Net proceeds are intended for working capital, loan repayment and general corporate purposes, with the offering relying on Section 4(a)(2) and Rule 506(b) exemptions.

Catheter Precision, Inc. is registering 68,067,042 shares of Common Stock for resale by existing holders, including shares issuable from multiple series of convertible preferred stock and warrants. The company will not receive any proceeds from these sales, though it will bear registration expenses.

The capital structure includes Series C-1, C-2, C-3, C-4 and D preferred stock with variable conversion prices tied to trading levels, a large potential Series C-4 facility, related‑party Series J preferred stock and Series M warrants, all convertible into Common Stock subject to ownership limits and floor-price conditions. As of July 10, 2026, 3,609,471 Common shares were outstanding, and the prospectus warns that full issuance of registered conversion shares could cause substantial dilution for current stockholders.

Catheter operates two segments: cardiac electrophysiology, built around its VIVO mapping system and LockeT suture retention device, and a newer private aviation platform acquired through FLYTE and Ponderosa Air, which generated approximately $0.2 million of revenue for the quarter ended March 31, 2026. The company reports limited cash, a significant working capital deficit and a going‑concern warning, and plans to use earlier private‑placement proceeds mainly to repay debt, restructure legacy catheter operations and simplify its balance sheet.

Catheter Precision, Inc. is registering 68,067,042 shares of common stock for resale by existing investors. These shares include 392,608 already outstanding shares, plus stock issuable from multiple preferred series (C-1, C-2, C-3, D, J) and Series M warrants. The company will receive no proceeds from these sales, while existing holders face very high potential dilution: as of July 2, 2026, only 3,609,471 shares were outstanding, and the prospectus notes that issuance of the covered stock could raise the share count by about 25.3 times and represent roughly 96.2% of post‑issuance shares. The filing also details heavy reliance on recent private placements, significant debt assumed in the FLYTE aviation acquisition, restrictive financing covenants, and an auditor’s substantial doubt about the company’s ability to continue as a going concern.

Catheter Precision, Inc. is registering 68,067,042 shares of common stock for resale by existing security holders, and will not receive any proceeds from these stockholder sales. As of June 22, 2026, there were 2,692,473 shares of common stock issued and outstanding.

The registered shares include common stock issued or issuable upon conversion of multiple series of preferred stock and related warrants, as well as shares tied to the acquisition of private aviation company FLYTE and related financings. The company highlights that issuing these shares could significantly increase its outstanding share count and cause substantial dilution to existing holders. The prospectus also notes liquidity pressures, assumed and new debt tied to the FLYTE acquisition, and an auditor statement expressing substantial doubt about the company’s ability to continue as a going concern.

Catheter Precision, Inc. entered a Securities Purchase Agreement to buy 2,941,176 shares of Volato Group, Inc. common stock in a private placement at $0.34 per share, for a total Subscription Amount of $1,000,000. As of June 5, 2026, the market value of these Volato securities was approximately $1,000,000.

As consideration for participating, Catheter Precision will receive certain freely tradeable equity securities of a third-party entity from Volato, which had an aggregate market value of about $1,100,000 as of June 5, 2026. Closing is subject to customary conditions, including accuracy of representations, covenant performance, and no Material Adverse Effect for Volato.

Under a related Registration Rights Agreement, Volato must file a registration statement on Form S-3 (or other appropriate form) to cover resale of the shares within 10 calendar days and use best efforts to have it declared effective under specified timing. The agreements include customary covenants, indemnities, and registration procedures.